First all-female TAVI study shows excellent results for women receiving Edwards valves

Edwards Lifesciences (NYSE: EW) today announced results from the RHEIA Trial, a first-of-its-kind study focused exclusively on outcomes for women undergoing transcatheter aortic valve implantation (TAVI). Presenting the one-year results during a Hot Line session at ESC Congress 2024, researchers reported improved outcomes for women who received the Edwards SAPIEN 3 Ultra or SAPIEN 3 Ultra RESILIA valves compared to women who underwent surgical aortic valve replacement (SAVR).

“Women are an underrepresented group in the diagnosis and treatment of severe aortic stenosis, and this landmark study provides important insights into their treatment options,” said Hélène Eltchaninoff, MD, head of the cardiology department at Rouen University Hospital. “The transcatheter and surgical arms achieved remarkable results, and the performance of the transcatheter valves adds to a growing body of evidence on the treatment options available to women.”